Led by a team of industry experts, 3R Pharma LTD is developing high-end and complex cannabinoids based therapies to address chronic ocular diseases for patients around the world.

We have partnered with CanNegev Incubator that was established as a joint venture of Perrigo/Padagis, BOL Pharma, OurCrowd, and Israeli Innovation Authority, and received seed funding from the Israeli Innovation Authority to initiate our research.

Our Research and Development unit is based in Israel and is licensed to conduct scientific and clinical research on cannabinoid formulations. As such, we are conducting in-depth research and developing cannabinoid-based therapies for patients suffering from complex chronic ophthalmic conditions such as blepharitis, meibomian gland disfunction and dry eye.

We are committed to developing the next generation of ocular therapeutics with the help of cannabinoids. These patent-pending cannabinoid-based therapies provide a novel treatment option for various ocular conditions that are currently insufficiently addressed.